Fig. 7: Safety of C-JUN-overexpressing CD33 CAR T cells in patients with r/r AML. | Nature Communications

Fig. 7: Safety of C-JUN-overexpressing CD33 CAR T cells in patients with r/r AML.

From: C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial

Fig. 7

A CONSORT diagram of the clinical trial. B Swimmer plot (n = 4) demonstrating the occurrence of CRS and ICANS after the infusion of CAR T cells. Each bar represents an individual patient. The severity is indicated by different colors. C CRS and ICANS management with etanercept in patient 2, n = 1. D The peak numbers of CAR T cells in PB of patients according to the grade of CRS, GVHD, and ICANS. Each dot represents one patient, n = 4. E Kinetics of serum cytokines for all patients in the first 30 days after CAR T-cell infusion. Each line represents one patient, n = 4. F Kinetics of monocyte, neutrophil, and thrombocyte counts in PB at different time points post-infusion. Each line represents one patient, n = 4. CRS cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, GVHD Graft-versus-Host Disease. Source data are provided in the Source Data file.

Back to article page